1. Home
  2. FAX vs OVID Comparison

FAX vs OVID Comparison

Compare FAX & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Asia-Pacific Income Fund Inc.

FAX

abrdn Asia-Pacific Income Fund Inc.

N/A

Current Price

$12.23

Market Cap

532.5M

Sector

Finance

ML Signal

N/A

Logo Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

N/A

Current Price

$2.21

Market Cap

479.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FAX
OVID
Founded
1986
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
532.5M
479.4M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FAX
OVID
Price
$12.23
$2.21
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
★ $6.15
AVG Volume (30 Days)
213.8K
★ 2.3M
Earning Date
01-01-0001
11-10-2026
Dividend Yield
★ 12.09%
N/A
EPS Growth
N/A
★ 3.90
EPS
★ N/A
N/A
Revenue
N/A
★ $7,252,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1181.27
52 Week Low
$12.43
$1.26
52 Week High
$16.37
$3.11

Technical Indicators

Market Signals
Indicator
FAX
OVID
Relative Strength Index (RSI) 30.28 41.03
Support Level N/A $2.12
Resistance Level $14.69 $2.67
Average True Range (ATR) 0.17 0.24
MACD -0.03 -0.05
Stochastic Oscillator 10.48 4.30

Price Performance

Historical Comparison
FAX
OVID

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Share on Social Networks: